The safe use of the CredibleMeds® lists of medications requires that the user have the most up-to-date lists and be aware when changes have been made. Therefore, we wish to inform you of the following:
We have evaluated the evidence for Roxithromycin (brand names Rulide®, Xthrocin®, Roxl-150®, Roxo®, Surlid®, Rulide®, Biaxsig®, Roxar®, Roximycinv®, Roxomycin®, Rulid®, Tirabicin® and Coroxin®), an antibiotic marketed outside the US that is now on our Possible Risk List, and found credible evidence of risk of Torsades de Pointes (TdP). Therefore, we have moved it from the Possible Risk list to the Known Risk list.
We also evaluated the antipsychotic drugs flupentixol (Depixol® or Fluanxol®) and tiapride (Tiapridal®, Italprid® and several others) also marketed outside the US and found substantial evidence of QT prolongation but only limited evidence of TdP. Therefore, these drugs have been added to the list with Possible Risk of TdP.
Also, because these three drugs cause QT prolongation, they will also be on the list of Drugs to Avoid (if at all possible) in patients with Congenital Long QT Syndrome.
Thank you for your support of CredibleMeds.org.